Literature DB >> 16214839

Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling.

Szilard Voros1, Zequan Yang, Christina M Bove, Wesley D Gilson, Frederick H Epstein, Brent A French, Stuart S Berr, Sanford P Bishop, Mark R Conaway, Hiroaki Matsubara, Robert M Carey, Christopher M Kramer.   

Abstract

The relative contribution of the angiotensin II type 1 and 2 receptors (AT1-R and AT2-R) in postmyocardial infarction (MI) remodeling remains incompletely understood. We studied five groups of C57Bl/6 mice after 1 h of left anterior descending artery occlusion-reperfusion: 1) wild type, untreated (n = 12); 2) wild type, treated with the AT1-R blocker losartan (10-20 mg.kg(-1).day(-1) in drinking water) from day 1 to day 28 post-MI (n = 10); 3) cardiac overexpression of the AT2-R [AT2-transgenic (TG); n = 14]; 4) AT2-TG treated with losartan (n = 13); and 5) AT2-TG and null for the AT1a-R [AT2-TG/AT1 knockout (KO); n = 10]. Cardiac magnetic resonance imaging (CMR) measured ejection fraction and left ventricular end-diastolic and end-systolic volume (EDVI and ESVI) and mass indexed to weight on days 0, 1, 7, and 28 post-MI. Infarct size was measured on day 1 by late gadolinium-enhanced CMR. Regional myocyte hypertrophy and collagen content were measured on day 28 post-MI. Infarct size was similar among groups. Systolic blood pressure was lowest in AT2-TG/AT1KO. By day 28 post-MI, when corrected for baseline differences, EDVI and ESVI were higher and ejection fraction was lower in wild type than other groups. Ejection fraction was highest and EDVI and mass index were lowest in AT2-TG/AT1KO at day 28. The AT2-TG/AT1KO demonstrated less fibrosis in adjacent regions. Regional myocyte hypertrophy was similar in all groups. The AT1-R and AT2-R are intricately intertwined in post-MI remodeling. Pharmacological blockade of AT1-R is equivalent to AT2-R overexpression in attenuating post-MI remodeling. Genetic knockout of the AT1a-R is additive to AT2-R overexpression, due, at least in part, to blood pressure lowering.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214839     DOI: 10.1152/ajpheart.00886.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  11 in total

1.  Cardiac magnetic resonance imaging in small rodents using clinical 1.5 T and 3.0 T scanners.

Authors:  Wesley D Gilson; Dara L Kraitchman
Journal:  Methods       Date:  2007-09       Impact factor: 3.608

2.  Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction.

Authors:  Jie Liu; Catherine Gu; E Bernadette Cabigas; Karl D Pendergrass; Milton E Brown; Ying Luo; Michael E Davis
Journal:  Biomaterials       Date:  2013-02-19       Impact factor: 12.479

Review 3.  AT2 receptors targeting cardiac protection post-myocardial infarction.

Authors:  Elena Kaschina; Dilyara Lauer; Patrick Schmerler; Thomas Unger; U Muscha Steckelings
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

4.  Nitroxide-enhanced MRI of cardiovascular oxidative stress.

Authors:  Soham A Shah; Sophia X Cui; Christopher D Waters; Soichi Sano; Ying Wang; Heather Doviak; Jonathan Leor; Kenneth Walsh; Brent A French; Frederick H Epstein
Journal:  NMR Biomed       Date:  2020-07-09       Impact factor: 4.044

5.  Angiotensin receptors alter myocardial infarction-induced remodeling of the guinea pig cardiac plexus.

Authors:  Jean C Hardwick; Shannon E Ryan; Emily N Powers; E Marie Southerland; Jeffrey L Ardell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-05-06       Impact factor: 3.619

6.  A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice.

Authors:  Alexander B Jehle; Yaqin Xu; Joseph M Dimaria; Brent A French; Frederick H Epstein; Stuart S Berr; Rene J Roy; Brandon A Kemp; Robert M Carey; Christopher M Kramer
Journal:  J Cardiovasc Pharmacol       Date:  2012-04       Impact factor: 3.105

Review 7.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 8.  RAS inhibition in resident fibroblast biology.

Authors:  Alexandra M Garvin; Bilal S Khokhar; Michael P Czubryt; Taben M Hale
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

Review 9.  LOX-1 and angiotensin receptors, and their interplay.

Authors:  Xianwei Wang; M Ian Phillips; Jawahar L Mehta
Journal:  Cardiovasc Drugs Ther       Date:  2011-10       Impact factor: 3.727

10.  Effects of deep sedation or general anesthesia on cardiac function in mice undergoing cardiovascular magnetic resonance.

Authors:  Christopher J Berry; Daniel R Thedens; KellyAnn Light-McGroary; Jordan D Miller; William Kutschke; Kathy A Zimmerman; Robert M Weiss
Journal:  J Cardiovasc Magn Reson       Date:  2009-05-19       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.